Lilly settles state litigation over Zyprexa marketing
Executive Summary
Lilly agrees to pay $62 million to 32 states and the District of Columbia to resolve an investigation of its promotional practices for Zyprexa (olanzapine). The company agrees not to promote the antipsychotic drug for off-label uses and to disclose its grants and payments to promotional speakers and consultants. It also agrees not to use certain statistical analyses in reporting Zyprexa trial results. The states reached a similar agreement with Merck regarding Vioxx promotions (1"The Pink Sheet," May 26, 2008, p. 22)